Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Hydrochlorothiazide

First Posted Date: 2009-06-23

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 894

Registration Number: NCT00926289

Locations: 🇺🇸
502.550.01007 Boehringer Ingelheim Investigational Site, Greensboro, North Carolina, United States
🇨🇳
502.550.86002 Boehringer Ingelheim Investigational Site, Shanghai, China
🇨🇳
502.550.86007 Boehringer Ingelheim Investigational Site, Tianjin, China

and more 103 locations

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin + metformin
Drug: Linagliptin+metformin
Drug: Metformin

First Posted Date: 2009-06-08

Last Posted Date: 2014-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 567

Registration Number: NCT00915772

Locations: 🇨🇦
1218.52.11003 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦
1218.52.11002 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada
🇭🇷
1218.52.38502 Boehringer Ingelheim Investigational Site, Karlovac, Croatia

and more 109 locations

Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study

Completed

Conditions: Hypertension

First Posted Date: 2009-05-27

Last Posted Date: 2014-06-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2411

Registration Number: NCT00909038

Locations: 🇫🇷
Boehringer Ingelheim Investigator site 359, La Tour Du Crieu, France
🇫🇷
Boehringer Ingelheim Investigator site 360, La Turballe, France
🇫🇷
Boehringer Ingelheim Investigator site 361, La Varenne St Hilaire, France

and more 912 locations

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992 low (20mg) dosage
Drug: BIBW 2992 medium (40mg) dosage
Drug: BIBW 2992 high (50mg) dosage
Drug: Vinorelbine i.v. 25 mg/m²
Drug: Vinorelbine per os 60 mg/m²
Drug: Vinorelbine per os 80 mg/m²

First Posted Date: 2009-05-21

Last Posted Date: 2014-06-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 55

Registration Number: NCT00906698

Locations: 🇫🇷
1200.69.3301 Boehringer Ingelheim Investigational Site, Toulouse Cedex, France
🇫🇷
1200.69.3302 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France

A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Nevirapine Immediate Release (IR)
Drug: Nevirapine Extended Release (XR)

First Posted Date: 2009-05-20

Last Posted Date: 2016-01-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT00905489

Locations: 🇿🇦
1100.1518.2703 Boehringer Ingelheim Investigational Site, Parow Valley, South Africa
🇺🇸
1100.1518.0001 Boehringer Ingelheim Investigational Site, Washington, District of Columbia, United States
🇺🇸
1100.1518.0002 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States

and more 7 locations

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Phase 1

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 207127 low dose + SOC
Drug: BI 207127 middle dose +SOC
Drug: BI 207127 high dose+SOC
Drug: Placebo + SOC

First Posted Date: 2009-05-20

Last Posted Date: 2016-04-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 75

Registration Number: NCT00905632

Locations: 🇫🇷
1241.7.3307A CHU de Grenoble, Grenoble cédex 9, France
🇫🇷
1241.7.3303A Hôpital Claude Huriez, Lille, France
🇩🇪
1241.7.49011 Boehringer Ingelheim Investigational Site, Freiburg, Germany

and more 15 locations

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: BIBF 1120
Drug: mFolfox 6
Drug: mFolfox
Drug: bevacizumab

First Posted Date: 2009-05-20

Last Posted Date: 2015-02-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 128

Registration Number: NCT00904839

Locations: 🇫🇷
1199.51.3306C Boehringer Ingelheim Investigational Site, Nice Cedex 2, France
🇫🇷
1199.51.3305A Boehringer Ingelheim Investigational Site, Toulouse cedex 3, France
🇫🇷
1199.51.3308B Boehringer Ingelheim Investigational Site, Saint Herblain, France

and more 44 locations

An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension

Completed

Conditions: Hypertension

First Posted Date: 2009-05-19

Last Posted Date: 2014-04-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1095

Registration Number: NCT00904215

Locations: 🇰🇷
Boehringer ingelheim Investigational Site 4, Daegu, Korea, Republic of
🇰🇷
Boehringer ingelheim Investigational Site 1, Daegu, Korea, Republic of
🇰🇷
Boehringer ingelheim Investigational Site 9, Daejeon, Korea, Republic of

and more 8 locations

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

Completed

Conditions: Hypertension
Cardiovascular Diseases

First Posted Date: 2009-05-19

Last Posted Date: 2012-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 211

Registration Number: NCT00904371

Locations: 🇸🇮
Boehringer Ingelheim Investigational Site 23, Golnik, Slovenia
🇸🇮
Boehringer Ingelheim Investigational Site 24, Brezice, Slovenia
🇸🇮
Boehringer Ingelheim Investigational Site 32, Golnik, Slovenia

and more 33 locations

Telmisartan Tab Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)

First Posted Date: 2009-04-29

Last Posted Date: 2014-04-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2913

Registration Number: NCT00890084

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy